Article

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes

2024-03-04

Abstract excerpt

<title>Abstract</title> <p> Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase and emerging therapeutic target that is overexpressed in most castration-resistant prostate cancers and implicated as a driver of disease progression and resistance to hormonal therapies. Here we define the lineage-specific action and differential activity of EZH2 in both prostate adenocarcinoma (PRAD) and neuroendocrin...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 96591596-f2de-52f7-a8d6-79156d07d101
DOI: 10.21203/rs.3.rs-3935288/v2

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypesDOI 10.21203/rs.3.rs-3935288/v2Read

EZH2 alters aggressive variant prostate cancer subtype evolution, but is not required for neuroendocrine prostate cancerSemantic proximity Read

N-Myc–mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancerSemantic proximity Read

Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancerSemantic proximity Read

The epigenetic and transcriptional landscape of neuroendocrine prostate cancerSemantic proximity Read

Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolutionSemantic proximity Read

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate CancerSemantic proximity Read

Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines.Semantic proximity Read

Targeting Wnt/EZH2/microRNA-708 signaling pathway inhibits neuroendocrine differentiation in prostate cancerSemantic proximity Read

NKX2-1 drives neuroendocrine transdifferentiation of prostate cancer via epigenetic and 3D chromatin remodelingSemantic proximity Read

Pharmacological targeting of EED is an effective therapeutic strategy in cellular models of incurable neuroendocrine prostate cancerSemantic proximity Read

Collaboration of Kras and Androgen Receptor Signaling Stimulates EZH2 Expression and Tumor-Propagating Cells in Prostate CancerSemantic proximity Read

PROX1 is an early driver of lineage plasticity in prostate cancerSemantic proximity Read